close

Agreements

Date: 2017-12-05

Type of information: Collaboration agreement

Compound: biomarkers

Company: Crossbeta Biosciences (The Netherlands) Probiodrug (Germany)

Therapeutic area: Neurodegenerative diseases

Type agreement: collaboration

Action mechanism: biomarker

Disease: Alzheimer's disease

Details:

  • • On June 30, 2016, Probiodrug announced an agreement with the Dutch biotech company Crossbeta Biosciences in order to utilize Crossbeta’s proprietary technology in support of Probiodrug’s biomarker development activities.
  • Alzheimer’s disease is characterized by misfolded beta-amyloid and tau proteins. The oligomeric forms of these proteins play a pivotal role in the patho-physiology of the disease. However these protein aggregates are very instable. Crossbeta’s proprietary stabilization technology generates pure and functional preparations of oligomeric protein species and thereby overcomes this problem, enabling highly reproducible and well-controlled assays for pre-clinical and clinical R&D. This technology will be used to establish and to validate specific assays for Abeta- and pGlu-Abeta-oligomers to be used in the clinical studies of Probiodrug’s lead candidate, Glutaminyl Cyclase (QC) inhibitor PQ912.
 

Financial terms:

Latest news:

  • • On December 5, 2017, Probiodrug and Crossbeta Biosciences announced that they have extended their strategic partnership regarding the use of Crossbeta's proprietary technology for biomarker development, in support of Probiodrug's clinical program in Alzheimer's disease. The companies first established the partnership in 2016. Since then, the very challenging program, focused on oligomer-specific biomarker assays and diagnostics, has successfully met all critical milestones. By leveraging the pivotal role of protein oligomers in AD pathology, the partners are aiming to develop a truly disease-specific AD biomarker and diagnostic with prognostic clinical value. Inge Lues, Chief Development Officer of Probiodrug, commented: "Our partnership with Crossbeta has granted us access to a truly unique technology which has proven to be crucially important for the development of high-quality biomarker assays, with adequate sensitivity and specificity to support and further the clinical program of Probiodrug's QC inhibitor PQ912."

Is general: Yes